Alector Appoints Dr. Arnon Rosenthal as CSO
Ticker: ALEC · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1653087
| Field | Detail |
|---|---|
| Company | Alector, INC. (ALEC) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-appointment, biotech
TL;DR
Alector just hired a new CSO, Dr. Arnon Rosenthal, to lead their neurodegenerative disease research.
AI Summary
On January 9, 2025, Alector, Inc. announced the appointment of Dr. Arnon Rosenthal as Chief Scientific Officer. Dr. Rosenthal brings extensive experience in neurodegenerative disease research and drug development to Alector. This appointment is expected to bolster Alector's scientific leadership as it advances its pipeline of therapies for neurodegenerative diseases.
Why It Matters
The appointment of a new Chief Scientific Officer with deep expertise in neurodegenerative diseases signals a strategic focus on advancing Alector's drug development pipeline in this critical area.
Risk Assessment
Risk Level: medium — The appointment of a new CSO is a significant leadership change that could impact the company's strategic direction and research progress.
Key Players & Entities
- Alector, Inc. (company) — The company filing the report.
- Dr. Arnon Rosenthal (person) — Newly appointed Chief Scientific Officer.
- January 09, 2025 (date) — Date of the earliest event reported.
FAQ
Who has been appointed as the new Chief Scientific Officer at Alector, Inc.?
Dr. Arnon Rosenthal has been appointed as the new Chief Scientific Officer.
What is the effective date of this report?
The earliest event reported is dated January 09, 2025.
What is Alector, Inc.'s primary business focus?
Alector, Inc. is focused on Biological Products, specifically in the area of neurodegenerative diseases.
What is Alector, Inc.'s principal executive office address?
Alector, Inc.'s principal executive offices are located at 131 Oyster Point Blvd., Suite 600, South San Francisco, California 94080.
What is Alector, Inc.'s telephone number?
Alector, Inc.'s telephone number is (415) 231-5660.
Filing Stats: 485 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-01-10 08:00:09
Filing Documents
- alec-20250109.htm (8-K) — 36KB
- 0000950170-25-003811.txt ( ) — 146KB
- alec-20250109.xsd (EX-101.SCH) — 24KB
- alec-20250109_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. Alector, Inc. (the "Company") was developing AL002, its TREM2 program asset, to treat patients with early Alzheimer's disease (AD) in collaboration with AbbVie Biotechnology, Ltd. ("AbbVie") under the Co-Development and Option Agreement, dated as of October 16, 2017, between the parties, as amended on February 13, 2023 (the "AbbVie Agreement"). As announced on November 25, 2024, the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early AD did not meet its primary endpoint. On January 9, 2025, AbbVie provided written notice to the Company terminating the TREM2 program. As that program is the only remaining program under the AbbVie Agreement, such termination also terminates the AbbVie Agreement. The Company and AbbVie have agreed that such termination will be effective 30 days from the receipt of the termination letter.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALECTOR, INC. Date: January 10, 2025 By: /s/ Marc Grasso Marc Grasso, M.D. Chief Financial Officer